Antitrust regulators to increase scrutiny of biosimilar deals

US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK regulators no longer exempt from paying successful parties' costs

26 May 2022 The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.

Americas

FDA, FTC send message to biologics makers at competition workshop

10 March 2020 US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.

Americas

Judge refuses to block pay-for-delay law pending appeal

13 January 2020 A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Antitrust regulators to increase scrutiny of biosimilar deals

More on this story

Editor's picks

Editor's picks

More features